John Berberian, NP
Nurse Practitioner · Burbank
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 12 years
- Graduated 2014
Offices
1 location · Foveo Healthcare A Professional Medical Corporation · 2 clinicians in this group
Looking this up.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call John Berberian’s office at (818) 254-9967 to ask if they take your plan before you enroll.
Medicaid work
$21,670 in 2023
Medicaid paid $21,670 for 327 billed services this clinician did in 2023, up to 39 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 127 | $21,670 |
| Short return visit | 103 | $0 |
| Short return visit (20+ min) | 97 | $0 |
| 2023 | 327 | 3 | 39 | $21,670 |
| 2022 | 3,125 | 6 | 164 | $204,209 |
| 2021 | 5,514 | 4 | 153 | $381,388 |
| 2020 | 794 | 5 | 71 | $54,989 |
See the largest Medicaid services in earlier years
2022
| Clinic visit/encounter, all-inclusive | 1,087 | $183,013 |
| Short return visit (20+ min) | 1,598 | $12,963 |
| Return visit (30+ min) | 240 | $5,059 |
| Psychiatric diagnostic evaluation with medical services | 40 | $1,888 |
| Short return visit | 91 | $1,285 |
| New patient visit (45+ min) | 69 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 1,902 | $312,761 |
| Return visit (30+ min) | 3,177 | $60,252 |
| Short return visit (20+ min) | 352 | $4,848 |
| Psychiatric diagnostic evaluation with medical services | 83 | $3,527 |
2020
| Clinic visit/encounter, all-inclusive | 327 | $46,532 |
| Return visit (30+ min) | 271 | $5,259 |
| Psychiatric diagnostic evaluation with medical services | 37 | $1,830 |
| Short return visit (20+ min) | 145 | $1,369 |
| New patient visit (45+ min) | 14 | $0 |
Drugs they prescribed that Part D paid
$187,117
Pharmacies billed $187,117 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 712) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
672 generic and 40 brand-name prescriptions · $187,117 in drug cost · 99 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ingrezza | 13 | $106,820 | $8,217 |
| Uzedy | 13 | $30,886 | $2,376 |
| Aripiprazole | 43 | $687 | $16 |
| Olanzapine | 32 | $641 | $20 |
| Sertraline | 83 | $421 | $5 |
See all 17 drugs
| Ingrezza | 13 | $106,820 | $8,217 |
| Uzedy | 13 | $30,886 | $2,376 |
| Aripiprazole | 43 | $687 | $16 |
| Olanzapine | 32 | $641 | $20 |
| Sertraline | 83 | $421 | $5 |
| Escitalopram | 90 | $399 | $4 |
| Mirtazapine | 58 | $383 | $7 |
| Gabapentin | 97 | $348 | $4 |
| Bupropion Xl | 21 | $184 | $9 |
| Trazodone | 53 | $182 | $3 |
| Fluoxetine | 19 | $120 | $6 |
| Quetiapine | 31 | $108 | $3 |
| Zolpidem | 17 | $78 | $5 |
| Duloxetine | 16 | $72 | $5 |
| Venlafaxine Hcl Er | 17 | $72 | $4 |
| Paroxetine | 12 | $64 | $5 |
| Bupropion Hcl Sr | 11 | $48 | $4 |
Year by year
| 2024 | 712 | 56 | 0% (0) | 6% | $187,117 |
| 2023 | 134 | 27 | 0% (0) | 0% | $3,994 |
| 2022 | 207 | 27 | 0% (0) | None | $6,141 |
| 2021 | 217 | 27 | 0% (0) | 0% | $2,243 |
| 2020 | 511 | 49 | 0% (0) | 4% | $47,060 |
| 2019 | 37 | 12 | 0% (0) | None | $8,855 |
| 2017 | 31 | 14 | None | None | $826 |
| 2016 | 49 | 20 | None | None | $4,740 |
| 2015 | 17 | None | 0% (0) | None | $1,228 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Aripiprazole | 16 | $2,375 | $148 |
| Sertraline | 21 | $304 | $14 |
| Gabapentin | 28 | $182 | $7 |
| Mirtazapine | 12 | $149 | $12 |
| Escitalopram | 14 | $91 | $7 |
2022: 4 drugs
| Escitalopram | 52 | $424 | $8 |
| Quetiapine | 16 | $327 | $20 |
| Gabapentin | 22 | $178 | $8 |
| Trazodone | 11 | $125 | $11 |
2021: 8 drugs
| Escitalopram | 54 | $390 | $7 |
| Quetiapine | 24 | $309 | $13 |
| Lamotrigine | 12 | $153 | $13 |
| Gabapentin | 24 | $119 | $5 |
| Lithium Carbonate | 11 | $111 | $10 |
| Zolpidem | 11 | $99 | $9 |
| Trazodone | 14 | $89 | $6 |
| Mirtazapine | 16 | $81 | $5 |
2020: 15 drugs
| Latuda | 11 | $16,821 | $1,529 |
| Aripiprazole | 35 | $1,425 | $41 |
| Quetiapine | 50 | $935 | $19 |
| Hydroxyzine | 30 | $533 | $18 |
| Buspirone | 57 | $478 | $8 |
| Sertraline | 41 | $381 | $9 |
| Oxcarbazepine | 12 | $298 | $25 |
| Olanzapine | 16 | $278 | $17 |
| Trazodone | 33 | $260 | $8 |
| Fluoxetine | 17 | $155 | $9 |
| Escitalopram | 39 | $130 | $3 |
| Lamotrigine | 13 | $126 | $10 |
| Mirtazapine | 15 | $102 | $7 |
| Gabapentin | 14 | $69 | $5 |
| Citalopram Hbr | 17 | $56 | $3 |
Money from drug and device companies
$1,649 in 2025
| 2025 | 7 | 27 | None | $1,649 |
| 2024 | 6 | 24 | None | $1,254 |
| 2023 | 7 | 14 | None | $733 |
| 2022 | 2 | 2 | None | $245 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Teva Pharmaceuticals USA | Austedo Xr | $513 | 7 payments
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $388 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Cobenfy | $242 | 4 payments
|
| Axsome Therapeutics | Auvelity | $179 | 4 payments
|
| Vanda Pharmaceuticals | Fanapt | $132 | 2 payments
|
| Otsuka America Pharmaceutical | Rexulti | $113 | 4 payments
|
See all 27 published payments
| Otsuka America Pharmaceutical | Meals · 2025-12-01 | Rexulti | $30 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-24 | Cobenfy | $28 |
| Axsome Therapeutics | Meals · 2025-11-21 | Auvelity | $1 |
| Axsome Therapeutics | Meals · 2025-11-21 | Auvelity | $32 |
| Teva Pharmaceuticals USA | Meals · 2025-11-18 | Austedo Xr | $31 |
| Otsuka America Pharmaceutical | Meals · 2025-11-13 | Rexulti | $32 |
| Vanda Pharmaceuticals | Meals · 2025-11-05 | Hetlioz | $32 |
| Otsuka America Pharmaceutical | Meals · 2025-10-28 | Rexulti | $25 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-10-28 | Caplyta | $142 |
| Vanda Pharmaceuticals | Meals · 2025-10-27 | Fanapt | $100 |
| Teva Pharmaceuticals USA | Meals · 2025-10-16 | Austedo Xr | $125 |
| Teva Pharmaceuticals USA | Meals · 2025-10-15 | Austedo Xr | $21 |
| Janssen Pharmaceuticals | Meals · 2025-10-08 | Spravato | $26 |
| Axsome Therapeutics | Meals · 2025-10-08 | Auvelity | $118 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-26 | Cobenfy | $41 |
| Otsuka America Pharmaceutical | Meals · 2025-09-23 | Rexulti | $26 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-08-05 | Caplyta | $120 |
| Teva Pharmaceuticals USA | Meals · 2025-07-30 | Uzedy | $128 |
| Janssen Pharmaceuticals | Meals · 2025-07-09 | Spravato | $15 |
| Axsome Therapeutics | Meals · 2025-06-25 | Auvelity | $28 |
| Teva Pharmaceuticals USA | Meals · 2025-05-16 | Austedo Xr | $25 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-25 | Cobenfy | $9 |
| Janssen Pharmaceuticals | Meals · 2025-04-19 | Spravato | $41 |
| Teva Pharmaceuticals USA | Education · 2025-04-03 | None | $80 |
| Teva Pharmaceuticals USA | Education · 2025-04-03 | None | $104 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-05 | Cobenfy | $164 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-02-06 | Caplyta | $125 |
See earlier years (2024, 2023, 2022)
2024: $1,254
| Teva Pharmaceuticals USA | Austedo Xr | $466 | 10 payments
|
| Janssen Pharmaceuticals | Spravato | $393 | 4 payments
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $136 | 2 payments
|
| Abbvie | Vraylar | $131 | 6 payments
|
| Vanda Pharmaceuticals | Fanapt | $108 | 1 payment
|
| Alkermes | Aristada | $19 | 1 payment
|
2023: $733
| Teva Pharmaceuticals USA | Austedo Xr | $269 | 3 payments
|
| Iti | Caplyta | $227 | 2 payments
|
| Abbvie | Vraylar | $105 | 5 payments
|
| Janssen Pharmaceuticals | Spravato | $53 | 1 payment
|
| Indivior | Perseris | $27 | 1 payment
|
| Alkermes | Aristada | $27 | 1 payment
|
| Neuronetics | Neurostar Tms Therapy System | $25 | 1 payment
|
2022: $245
| Neurocrine Biosciences | Ingrezza | $127 | 1 payment
|
| Iti | Caplyta | $118 | 1 payment
|
Professional record
- NPI
- 1518345180
- Licence
- CA NP95001794
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LP0808X (363LP0808X); Federal specialty code 363LF0000X (363LF0000X)
- Mailing address
- 500 E Olive Ave Ste 310, Burbank, CA, 91501
- NPI first listed
- 2015-05-14
- NPI last updated
- 2024-12-22
- NPI record certified
- 2024-12-22
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 451 W Lincoln Ave Ste 100, Anaheim, CA, 92805